Clinical Trials Browser

Unknown × Colorectal Neoplasms × HMPL-013 × Clear all

NCT06347198 2024-04-04

Oral Inulin in Combination With Fruquintinib Plus Sintilimab as Third- or Further-line Treatment in Metastatic Colorectal Cancer

Phase EARLY_PHASE1 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT05435313 2024-01-17

Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy

Phase 2 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT05522738 2024-01-08

Safety and Efficacy of Fruquintinib+FOLFIRI in RAS-mutated Metastatic Colorectal Cancer

Phase 1/2 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT05634590 2022-12-02

The Efficacy and Safety of Fruquintinib Plus FOLFIRI/FOLFOX as Second-line Treatment in Patients With RAS-mutant Metastatic Colorectal Cancer

Phase 2 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT05511051 2022-08-22

A Prospective Multi-centered Randomized Controlled Trial on Fruquintinib in Combination With HAIC in the Treatment of Liver Metastatic Colorectal Cancer After Failure of Second-line Systematic Therapy

Phase 2 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT05004831 2022-08-18

Fruquintinib Combined With TAS-102 in the Treatment of Patients With Advanced Metastatic CRC

Phase 2 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT05016869 2022-08-18

Fruquintinib Plus Capecitabine as Maintenance Treatment of RAS / BRAF Wild-type Metastatic Colorectal Cancer

Phase 1/2 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT04733963 2022-07-26

Fruquintinib Plus Capecitabine Versus Bevacizumab Plus Capecitabine as Maintenance Therapy Following First-line Treatment for Metastatic Colorectal Cancer

Phase 2 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT04866862 2022-07-25

Fruquitinib Combined With Camrelizumab in Non MSI-H/dMMR Refractory Colorectal Cancer

Phase 2 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT05451719 2022-07-12

Fruquintinib Plus Capecitabine Versus Capecitabine as Maintenance Therapy for Metastatic Colorectal Cancer After First-line Chemotherapy

Phase 2 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT05447715 2022-07-07

Fruquintinib Sequential BEV+FOLFIRI vs. BEV+FOLFIRI Sequential Fruquintinib in Metastatic Colorectal Cancer

Phase 2 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT05292417 2022-03-31

Radiotherapy in Combination With Sintilimab，GM-CSF and Fruquintinib in Patients With MSS mCRC

Phase 2 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT04948034 2021-08-27

The Combination of Fruquintinib, Tislelizumab and Stereotactic Ablative Radiotherapy in Metastatic Colorectal Cancer(RIFLE)

Phase 2 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT03977090 2021-02-10

Geptanolimab(GB226) Combined With Fruquintinib in the Treatment of Metastatic Colorectal Cancer

Phase 1 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT04695470 2021-01-07

Phase II Trial of Fruquintinib With Sintilimab in Treating Selected Refractory Metastatic Colorectal Cancer Patients

Phase 2 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT04431791 2020-06-16

Real World Study of Regorafenib Versus Fruquintinib in Colorectal Cancer

Gastrointestinal

Colorectal Neoplasms